Abstract We compared the proportion of cases of community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus (CA-MRSA and HA-MRSA, respectively) bacteraemia among patients at five hospitals in the Gauteng and Western Cape provinces in South Africa and described the molecular characteristics and antimicrobial susceptibility trends. This was a crosssectional study using data collected by enhanced surveillance for S. aureus bacteraemia. A total of 2511 cases of S. aureus bacteraemia were identified from January 2013 to January 2016. Among 1914 cases of S. aureus, 557 (29.1%) cases were identified as MRSA infection. Fortyfour cases (44/1914 [2.3%] of all S. aureus cases) were considered CA-MRSA infection and 513/1914 (26.8% of all cases) had HA-MRSA infection; the majority were neonates. CA-MRSA constituted 7.9% (44/557) of all cases of MRSA infection. Staphylococcus aureus isolates demonstrated significantly reduced susceptibility to the following classes of antimicrobial agents: macrolides, tetracyclines, aminoglycosides and cotrimoxazole, in 2015 compared to 2013 (p < 0.05). Of the 557 MRSA isolates, 484 (87%) were typed for SCCmec elements and spa types: the most common SCCmec type was type III (n = 236, 48.76%), followed by type IV (n = 144, 29.76%). The most common spa types were t037 (n = 229, 47.31%) and t1257 (n = 90, 18.60%). Of 28 isolates selected for multilocus sequence typing (MLST), the most common sequence types (STs) were ST239 and ST612 of clonal complex 8 (CC8) (n = 8 each) and a novel ST (ST4121) was obtained for one isolate. This study demonstrates that S. aureus bacteraemia is common in South African academic centres and characterised by HA-MRSA SCCmec types III and IV. A small proportion of CA-MRSA cases were caused by a few different sequence types.
Introduction
Staphylococcus aureus is a major human pathogen that causes a wide range of clinical infections, such as bacteraemia, endocarditis, arthritis, osteomyelitis, lung infections, skin and soft tissue and device-related infections [1] . S. aureus is a commensal organism in about 30% of the human population [1] . The epidemiology of S. aureus bacteraemia has been poorly described in low-and middle-income countries (LMICs) compared to high-income countries (HICs) [1, 2] . While the case fatality rate for S. aureus bacteraemia was approximately 80% in the pre-antibiotic era, this has remained persistently high (15-50%) over the past several decades, owing partly to the emergence of methicillin-resistant S. aureus (MRSA) in the 1960s [1] . Historically, MRSA isolates, which are resistant to β-lactam antibiotics, were confined to healthcare facilities. However, in the mid-1990s, the emergence of communityassociated MRSA (CA-MRSA) strains, which cause infections among patients with no previous exposure to the healthcare environment, resulted in a considerable shift to CA-MRSA-associated disease in HICs in North America, Asia, Europe and Australia, but less so in LMICs [2] [3] [4] . The overall incidence of S. aureus bacteraemia has been stable over the past two decades, but MRSA rates have fluctuated and since 2005, HICs including the United States, Canada, United Kingdom, France and Australia have described significant reductions in MRSA bacteraemia through populationbased active surveillance [1, 5] . The incidence of CA-MRSA in LMICs is less well described and this highlights the need for surveillance in order to determine the burden of disease. This is not simple because CA-MRSA and HA-MRSA are not easily distinguished and case definitions for both involve numerous variables, such as epidemiological and clinical features, which are required in conjunction with molecular characterisation of a large staphylococcal cassette chromosome mec (SCCmec). SCCmec types I to III are traditionally assigned to hospital strains and types IV to VI to community strains, but this distinction has become less clear in the last few years. The largest proportion of cases of S. aureus bacteraemia (both methicillin-susceptible and -resistant) occurred among children aged less than one year old in a previous report from South Africa [6] . This report also showed a strong association between human immunodeficiency virus (HIV) infection and MRSA bacteraemia [6] .
To our knowledge, no South African studies have yet described the proportions of MRSA bacteraemia that are community-versus healthcare-associated using epidemiological, clinical and molecular criteria. In this study, we compared the proportion of cases of CA-MRSA and HA-MRSA bacteraemia among hospitalised patients at five sentinel surveillance hospitals in the Gauteng and Western Cape provinces in South Africa, evaluated factors associated with CA-MRSA versus HA-MRSA and compared in-hospital outcomes between the two groups. We also described the molecular characteristics and antimicrobial susceptibility trends over a three-year period, to guide clinicians in antimicrobial stewardship (AMS) programmes and to establish baseline antimicrobial resistance profiles of S. aureus isolates for guideline and policy formulation.
Methodology Study design and population
This was a cross-sectional study using data collected by active, laboratory-based surveillance for S. aureus bacteraemia, through the GERMS-SA enhanced surveillance programme. Five tertiary public-sector hospitals were included: Helen Joseph Hospital (HJH) with 900 beds serving an estimated population of 1 million, Steve Biko Academic Hospital at Tshwane District (SBAH) with 832 beds for a 402,980 population, Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) with 1088 beds intended for 4.4 million people from Gauteng Province, Groote Schuur Hospital (GSH) with 893 beds serving a population of 1.8 million from the Western Cape and Tygerberg Hospital (TBH) with 1384 beds serving a population of 1.9 million from the Western Cape that started surveillance one year later on 1st January 2014.
Case definitions
A case was defined as a person of any age accessing publicsector healthcare at any one of the five hospitals during the period of surveillance with a blood culture specimen positive for S. aureus. All positive specimens within 21 days of the first positive specimen contributed to a single case, while subsequent positive specimens were considered part of new cases. All cases of S. aureus bacteraemia, where S. aureus was found to be non-susceptible to oxacillin or cefoxitin, were classified as cases of MRSA infection.
Criteria to distinguish communityand hospital-associated MRSA A number of criteria were used to distinguish CA-from HA-MRSA bacteraemia. A case of CA-MRSA bacteraemia was defined as a patient with: (1) MRSA isolated from a blood culture specimen ≤ 48 h of admission to hospital and (2) no contact with a healthcare facility within one year prior to the current episode of MRSA infection (including prior dialysis, prior surgery and prior admission to a long-term care facility). A patient with MRSA isolated > 48 h after admission or with any prior healthcare contact was considered to be a case of HA-MRSA infection.
Data collection
GERMS-SA surveillance officers used standardised case report forms (CRFs) to collect demographic, clinical and treatment data from consenting patients with laboratory-confirmed S. aureus bacteraemia. Data were also obtained from medical and laboratory records. Isolates from these patients were submitted to the National Institute for Communicable Diseases (NICD) for confirmatory identification, antimicrobial susceptibility testing, confirmation of mecA gene and genotyping. Completeness of surveillance data was checked for the time period 1 January 2013 to 31 January 2016 using the National Health Laboratory Service Corporate Data Warehouse, which houses information from routine laboratory testing and reporting.
Statistical analysis
Demographic and clinical characteristics of cases were summarised and compared using Chi-squared/Fisher's exact tests for categorical data and Student's t-test/Wilcoxon ranked sum tests for continuous data. We calculated proportions by dividing the number of CA-MRSA and HA-MRSA cases by the total number of S. aureus bacteraemia cases, as well as by the number of cases with MRSA bacteraemia. Multivariable logistic regression analysis was performed to evaluate factors associated with CA-MRSA versus HA-MRSA and to compare in-hospital outcome between the two groups. Exposure variables (including age, sex, hospital, province, clinical diagnosis, body temperature at diagnosis, mental status, mechanical ventilation, cardiac arrest, prior MRSA, prior surgery, prior dialysis, previous admission to a long-term care facility, HIV infection, participation in contact sports, living or working in crowded facilities and pre-existing medical and surgical conditions) were independently evaluated as risk factors for MRSA type and mortality by univariate analysis. Variables with p-values < 0.2 were included by forward stepwise manual addition into two multivariable models. A p-value of < 0.05 in the multivariable models was considered statistically significant.
Microbiology

Phenotypic methods
S. aureus isolates were submitted by diagnostic laboratories on Dorset transport medium (Diagnostic Media Products, NHLS, Sandringham). Organism identification was confirmed using the Vitek 2 GP card (bioMérieux, France). Susceptibility testing was performed on the MicroScan WalkAway system (Siemens Healthcare Diagnostics, USA) using the Positive MIC Panel Type 33. Categorical results and susceptibility profiles of most tested antimicrobial agents were based on the Clinical and Laboratory Standards Institute (CLSI) interpretative criteria [7] ; for fosfomycin, the interpretation of minimum inhibitory concentrations (MICs) was performed by using European Committee on Antimicrobial Susceptibility Testing (EUCAST) interpretative criteria 2016 recommendations [8] and mupirocin MICs interpretation was based on manufacturer recommendations. The MIC 50 and MIC 90 (MICs needed to inhibit the growth of 50% and 90% of organisms, respectively) were determined for all tested agents.
Molecular methods
DNA extraction Pure bacterial colonies were re-suspended in 400 μL TE buffer. This was vortexed briefly and heated at 95°C for 25 min to allow bacterial cell lysis to release the DNA. Centrifugation followed at 12000 rpm for 3 min to pellet the cellular debris. The supernatant was then aliquoted and stored at − 70°C for further investigations. PCR screening for mecA and mecC genes in MRSA isolates The LightCycler 480 II instrument (Roche Applied Science, Germany) was used for the real-time polymerase chain reaction (PCR) amplification of the methicillin resistance determinant, mecA, and the species-specific gene, nuc, which were amplified in a multiplex assay using the LightCycler 480 Probes Master Kit (Roche Diagnostics, IN, USA) with previously published primers and probes [9] . In the absence of mecA, the G-Storm (Somerton Biotechnology Centre, UK) thermal cycler was used for conventional PCR-based amplification of the methicillin resistance determinant, mecC, using the QIAGEN Multiplex PCR Kit (Qiagen, Germany) with previously published primers [10] . SCCmec typing All mecA-positive MRSA isolates were typed by multiplex PCR using the QIAGEN Multiplex PCR Kit (Qiagen, Germany) and previously published primers [11] . spa typing The spa gene was amplified using previously published primers [12] and the AmpliTaq Gold DNA Polymerase Kit (Applied Biosystems, CA, USA). Purified PCR products (Qiagen Purification Kit; Qiagen, Germany) were sequenced (Inqaba Biotech, South Africa). Sequences were assembled using CLC Bio main workbench (Qiagen, Germany) and analysed using the Ridom StaphType™ software (Ridom GmbH, Würzburg, Germany). MLST For our healthcare-associated infection group (n = 513), four isolates belonging to each of the five most common spa types (t037, t1257, t012, t045 and t064) were selected for multilocus sequence typing (MLST). For our community-associated infection group (n = 44), the following spa types were observed: t037, t1257 t064 and t032. Two isolates belonging to the t037 and t1257 spa types were selected for MLST and one isolate each was observed and sequenced for the t064 and t032 spa types. Since t032 was observed in the community-associated infection group, we also included two isolates belonging to this sequence type (ST) in our healthcare-associated infection group. Primers amplifying seven reference genes were used [13] . Amplification was performed using the AmpliTaq Gold DNA Polymerase Kit (Applied Biosystems, CA, USA). Purified PCR products were sequenced (Inqaba Biotech, South Africa). Sequences were assembled using CLC Bio main workbench (Qiagen, Germany) and analysed using the online database at https://pubmlst.org.
Results
CA-MRSA and HA-MRSA
A total of 2511 cases of S. aureus bacteraemia were identified from January 2013 through to January 2016, including 597 cases with no corresponding isolates (missing or non-viable) detected by review of the laboratory information system. This accounted for 2414 discreet patients, as 76 patients had more than one episode of infection. Among 1914 cases of S. aureus bacteraemia with a viable isolate, confirmed molecular identification and full susceptibility profile, 557 (29.1%, 95% confidence interval [CI] 27.1-31.2) cases were classified as MRSA infection (Fig. 1 Antimicrobial susceptibility results for all S. aureus isolates All S. aureus blood culture isolates demonstrated significantly reduced susceptibility to the following classes of antimicrobial agents: β-lactams, macrolides, tetracyclines, aminoglycosides and cotrimoxazole, in 2015 compared to 2013 (p < 0.05), but not compared to 2014 (Fig. 3) . The MIC 50 and MIC 90 values of most antimicrobials were unchanged over the three-year period (Table 2 ). Figure 4 compares susceptibilities to antimicrobial agents and these were not significantly different for HA-MRSA versus CA-MRSA isolates, except for a higher proportion of HA-MRSA isolates resistant to rifampicin. We recorded 72 isolates with a vancomycin MIC of 2; 17 patients died, including ten with MRSA, and 48 recovered, including 38 patients with MRSA; the majority had SCCmec type III.
Cases of S. aureus bacteraemia (SAB) n = 2511
Cases of SAB with antimicrobial susceptibility testing results AST testing conducted n=1914
Community-associated MRSA (CA-MRSA) n=44
Hospital associated -MRSA (HA MRSA) n=513
Cases of methicillinsusceptible S. aureus (MSSA) bacteraemia n=1357
Cases of methicillinresistant S. aureus (MRSA) bacteraemia n=557 We analysed the 484 available isolates resistant to oxacillin and confirmed mecA in 483, except for one MRSA isolate that was negative for both mecA and mecC.
SCCmec typing
Of the 557 MRSA isolates, 484 (87%) were typed: the most common SCCmec type was SCCmec type III (n = 236, 48.76%), followed by types IV (n = 144, 29.76%), II (n = 42, 8.68%), VI (n = 4, 0.83%), V (n = 3, 0.62%) and I (n = 1, 0.21%); the rest of the isolates could not be typed (Fig.  5) . Unknown typing patterns were identified for 52 isolates (10.74%). Multiple banding patterns were observed and require further investigation. Two isolates produced no amplicons and therefore, no resultant SCCmec type. Overall, the SCCmec typing results showed a difference between the two provinces; a predominance of type III (n = 206/484, 43%) was observed in Gauteng and a predominance of type IV (n = 77/484, 16%) was seen in the Western Cape. Among the type IV isolates, the majority were unexpectedly of hospital origin and showed similar susceptibility to classes of antibiotics other than the β-lactams (Figs. 4 and 5 ).
Spa typing
Spa typing of 484 oxacillin-resistant isolates revealed 49 different spa types, 15 of which were novel and have not, as yet, been assigned. Two isolates could not be typed. The five most common spa types were t037 (n = 229, 47.31%), t1257 (n = 90, 18.60%), t045 (n = 44, 9.09%), t012 (n = 32, 6.61%) and t064 (n = 10, 2.07%), which accounted for 84% of the isolates tested. The majority (n = 214, 44.21%) of the SCCmec type III isolates belonged to spa type t037, the majority (n = 80, 16.53%) of the SCCmec type IV isolates belonged to spa type t1257 and the SCCmec types I, Vand VI accounted for only a few isolates. Spa CC064 (17% of all spa types) was the largest clonal complex (CC), followed by spa CC012 (15% of all spa types) and spa CC032/022 (9% of all spa types). Spa CC064 contained isolates displaying predominantly the SCCmec type IV element. Spa CC037 contained isolates that displayed predominantly SCCmec types III as well as types II, IV and unknown typing patterns (Table 4) . Spa CC064 and spa CC037 were identified in both Gauteng and the Western Cape [6, 7] . Table 3 shows the six most common spa types and correlating SCCmec types for healtcare-and community-associated infections. All six spa types and all represented SCCmec types were observed for healthcare-associated infections. For community-associated infections, SCCmec type III spa type t037 was observed for nine isolates, SCCmec type IV spa type t1257 was observed in 13 isolates and SCCmec type IV spa types t064 and t032 were observed in one isolate each.
MLST
The most common STs observed were ST239 and ST612, both belonging to CC8 (n = 8 each), followed by ST36 (CC30), ST5 (CC5) (n = 4 each) and ST22 (CC22) (n = 3) One isolate produced a novel ST (ST4121). The allelic profile was very similar to 13 existing STs on the MLST database, but differed by one allele (aroe). The 13 STs included the following: ST22, 44, 854, 927, 928, 970, 
V a n c o m y c i n 1 Table 4 .
Predisposing factors and clinical outcome
Among all patients with MRSA infection, HIV-infected patients were three times more likely to have CA-MRSA than HA-MRSA, after adjustment for age and sex (aOR: 3.3; 95% CI: 1.1-9.3). Fever (body temperature ≥ 37.5°C) at diagnosis of bacteraemia was associated with HA-MRSA (aOR: 0.2; 95% CI: 0.05-0.7) rather than CA-MRSA, while other underlying conditions such as diabetes mellitus and kidney disease were not associated with CA-MRSA ( (Tables 5, 6 ).
Discussion
To our knowledge, this is one of the largest epidemiological studies to describe S. aureus bacteraemia in South Africa; we analysed data from 1914 patients and compared cases of HA-MRSA and CA-MRSA infection. Overall, among cases of S. aureus bacteraemia, more than a quarter were due to MRSA, of which only eight percent were categorised as CA-MRSA. This prevalence estimate is much lower than that reported from studies in the United States, where the prevalence of CA-MRSA varied from 35% to 80% and suggests that the epidemiology of MRSA infection varies by region [5] . Our findings might also differ from other regions due to different criteria used to define cases of CA-MRSA infection. In contrast to a recent review by Tong et al. and reports from subSaharan Africa and North America of cases among adults, most cases of bloodstream MRSA infection in South Africa were diagnosed among infants and young children in the Gauteng province (42%) but not in the Western Cape (10%), perhaps due to overcrowding in paediatric wards [1, 5, 6] .
The ratio of MRSA to MSSA cases was stable over the study period. The prevalence of S. aureus bacteraemia over the three-year study period was also largely unchanged. This is different to the trend observed in the USA [2] . In this study, we also showed no evidence of replacement of HA-MRSA strains with CA-MRSA, unlike in HICs, where a majority of MRSA infections now originate in the community [5] . In the last few decades, the incidence of CA-MRSA has reportedly increased in HICs, while, in contrast, South Africa's epidemiology with a high proportion of HA-MRSA infection is similar to that reported from the African region in a study from Soweto and southern Europe [14, 15] . These variations may be explained by factors such as the risk profile of hospitalised patients. We found no difference in the epidemiology of CA-MRSA in two provinces with relatively well-resourced healthcare systems.
Interestingly, we found a dominance of SCCmec type III in Gauteng and type IV in the Western Cape. Type III in Gauteng province was associated mostly with spa type t037 and type IV with the spa type t1257. These were previously reported as dominant in these provinces [6] . The spa CC012 in these two provinces was similar to a study from Tygerberg Academic Table 3 SCCmec types and spa types observed for healthcare-associated (HA) and community-associated (CA) MRSA infections   II  III  IV  V  Total   t037  t1257  t012  t064  t037  t1257  t012  t045  t032  t037  t1257  t012  t064  t032  t045   H A  4  2  2 8  1  2 2 7  6  3  7  1  8  7 1  1  8  7  3  3 7 7  CA  9  13  1  1  24 Those representing the six most common spa types overall are included in this table. Untypable SCCmec types were excluded from this analysis Hospital [16] . When the six most common spa types (t037, t1257, t012, t045, t064 and t032) and SCCmec types were correlated, SCCmec types II, III, IVand Vand all six spa types were linked to healthcare-associated infections. SCCmec types III and IVand spa types t037, t1257, t064 and t032 were observed in community-associated infections. It should be noted that the majority of our isolates were regarded as healthcare-associated infections (n = 513) according to the definition used. The remaining 44 isolates were communityassociated infections. Regarding spa types, we confirmed that the majority of t037 (47%) and t1257 (17%) belonged mostly to the MLST CC8, unlike in the study of Breurec et al., where CC8 was the sporadic clone and the majority belonged to CC239 related to the Brazilian/Hungarian clone [17] . This was observed in isolates belonging to both healthcare-and community-associated infections. Of the six isolates that were spa type t037, one isolate was ST36 (CC30) as expected and the remaining five isolates belonged to ST239 (CC8). The latter is an unusual occurrence, which may be supported by a previous study in 2016 which has shown that genetic exchange and recombination can occur, resulting in isolates exhibiting spa types which are usually known from another core genome as indicated by MLST [18, 19] . One isolate produced a novel ST. The allelic profile for aroe differed when compared to all other existing MLST profiles and a new ST was assigned. The most common sequence types identified in this MRSA study were ST5, ST36, ST612 and ST239, with a predominance of SCCmec types III and IV. This is similar to other parts of the world, such as Europe and Australia. Similar to other African countries, ST239 related to the Brazilian/ 7775  IV  t064  612  8  HA  2013  8307  II  t012  36  30  HA  2014   8538  IV  t012  22  22  HA  2014   8544  III  t012  612  8  HA  2014  8204  Unknown  t037  239  8  HA  2014   8203  III  t037  239  8  HA  2014   8371  IV  t037  239  8  HA  2014  8401  II  t037  36  30  HA  2014   8366  III  t045  36 Unknown  t045  5  5  HA  2015  9509  Unknown  t1257  5  5  HA  2015  7730  IV  t064  612  8  CA  2013   8243  III  t037  239  8  CA  2014  9588  IV  t032  22  22  CA  2015  8853  III  t037  239  8  CA  2015   9018  IV  t1257  612  8  CA  2015  9316  IV  t1257  612  8  CA  2015 HA = Healthcare-associated infection; CA = community-associated infection a Novel ST. ST similar to the following 13 STs on the MLST database (http://saureus.beta.mlst.net/); however, the aroe allele differed: ST22, 44, 854, 927, 928, 970, 1037, 1645, 2037, 2892, 2893, 2894 and 3211. The CC is not assigned Hungarian clone was common in our hospital settings [17, 19] . There was no difference in molecular characteristics between the healthcare-and community-associated infection groups. Furthermore, no evolution of clonal types was observed from 2013 to 2015. HIV-infected persons were more likely to have CA-MRSA than HA-MRSA. This association might be explained by an overall increase in this group of incidence of S. aureus bacteraemia [1, 20] . In addition, fever at diagnosis was associated with HA-MRSA. These predisposing factors could potentially be used to construct a clinical algorithm for predicting whether a patient has CA-MRSA or HA-MRSA infection. In this study, we demonstrated that SCCmec type IV MRSA infections were common among patients in healthcare facilities, which makes it difficult to establish clear and objective differences between CA-MRSA and HA-MRSA strains [2] . The high crude in-hospital mortality of patients with both CA-MRSA and HA-MRSA infection was not a surprising finding and risk factors for mortality identified in the multivariable analysis, such as old age, heart conditions, patients on mechanical ventilation, previous MRSA infections and patients in long-term care facilities, are in keeping with previous studies [20] [21] [22] . No outcome difference was found between CA-MRSA versus HA-MRSA infections in our study, as indicated in a previous research where neonatal intensive care unit (NICU) patient characteristics were similar [23] .
Regarding the susceptibility pattern over the study period, S. aureus did not reveal a significant increase in antimicrobial resistance. There were non-significant differences of susceptibility to other antimicrobial agents between CA-and HA-MRSA. CA-MRSA isolates showed more susceptibility to erythromycin and clindamycin but not rifampin, which may be related to its use for the treatment and prevention of tuberculosis [15] . This finding is in keeping with reports of community-associated infections from the USA and Australia showing that CA-MRSA isolates were more susceptible to macrolides, aminoglycosides and fluoroquinolones [2] . A study from Portugal showed a decrease in the multidrug resistance profile in MRSA over a 20-year period [15] and a meta-analysis by Falagas et al. [4] showed varied susceptibility to various antibiotics. In hospitalised South African paediatric patients with bacteraemia, a high prevalence of MRSA was found in HIV-infected children [20] . We found no resistance to the following classes of antibiotics: glycopeptides, oxazolidines, quinupristin/dalfopristin and daptomycin in both groups.
Our study has a number of limitations. Firstly, the presence of SCCmec types IV, V and VI, as well as a non-multidrug resistance antimicrobial phenotype (isolates not resistant to two or more classes of non-β-lactam antibiotics) were considered for inclusion in the case definition. However, these criteria were not included in the final definition, as the number of cases with all four criteria was too low. This may have resulted in the misclassification of CA-MRSA cases as HA-MRSA. Secondly, the majority of our patients had bacteraemia with no origin, perhaps due to incomplete clinical data to indicate the origin of bacteraemia. Another limitation of our study was the inclusion of only academic centres in urban areas. Therefore, the results may not be representative of all healthcare facilities in South Africa [24] .
Conclusions
In conclusion, this study demonstrates that S. aureus bacteraemia is common in South African academic centres and healthcare-associated methicillin-resistant S. aureus (HA-MRSA) is still the dominant cause of MRSA bacteraemia. A small proportion of community-associated methicillin-resistant S. aureus (CA-MRSA) cases were caused by a few sequence types. The dominance of SCCmec type III existed; however, the presence of SCCmec type IV has become evident that this replacement is emerging in hospitals. We found no resistance to glycopeptides, oxazolidines, quinupristin/dalfopristin and daptomycin in both methicillinsusceptible S. aureus (MSSA) and MRSA. Our resistance profile of CA-MRSA isolates suggests that the macrolide 
GCS = Glasgow Coma Score
An odds ratio (OR) >1 suggests an association with CA-MRSA, while an OR < 1 suggests an association with HA-MRSA. Denominators differ due to missing data for certain variables group of agents should be used with caution or should be directed by results from susceptibility testing for the treatment of localised infections. We recommend continuous surveillance of S. aureus bacteraemia to monitor the trends of MRSA.
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